Form 4: ALX Oncology CEO Jason Lettmann Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
ALX Oncology's CEO, Jason Lettmann, sold 2,159 shares of common stock on February 19, 2025, to cover tax liabilities related to vesting restricted stock units.
Summary
- On February 19, 2025, Jason Lettmann, the CEO of ALX Oncology Holdings Inc., sold 2,159 shares of common stock.
- The sale was executed at a weighted average price of $1.1502 per share, with individual transactions ranging from $1.15 to $1.16.
- The purpose of the sale was to satisfy the reporting person's tax liability in connection with the vesting of restricted stock units.
- Following the transaction, Lettmann directly owns 170,270 shares of ALX Oncology.
- This includes 3,000 shares acquired under the Issuer's employee stock purchase plan on December 31, 2024.
Sentiment
Score: 5
Explanation: The document describes a routine transaction (stock sale for tax purposes) with no inherent positive or negative implications for the company's overall prospects.
Industry Context
Sales of shares to cover tax obligations are a routine part of executive compensation, particularly when dealing with equity-based compensation.
Key Dates
| Date | Description |
|---|---|
| December 31, 2024 | 3,000 shares acquired under the Issuer's employee stock purchase plan |
| February 19, 2025 | Date of stock sale transaction |
| February 21, 2025 | Date of Form 4 filing |
Keywords
ALX Oncology, Jason Lettmann, stock sale, Form 4, CEO, tax liability, restricted stock units, employee stock purchase plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.